loader
Please Wait
Applying Filters...

Seqens Seqens

X

Approved Drug Products containing 206073 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 BOEHRINGER INGELHEIM (2)

filter

01 TABLET;ORAL (2)

filter

01 RX (2)

filter

01 GLYXAMBI (2)

filter

01 Yes (2)

URL Supplier Web Content
TABLET; ORAL
10MG;5MG
2015-01-30
206073
GLYXAMBI
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
TABLET; ORAL
25MG;5MG
2015-01-30
206073
GLYXAMBI
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for FDA Orange Book APPLICATION 206073

Looking for FDA Orange Book APPLICATION 206073 2

19

Boehringer Ingelheim GmbH, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is EMPAGLIFLOZIN; LINAGLIPTIN, with a corresponding application number 206073.

Regulatory Information RX

With a dosage strength 10MG;5MG

Dosage Form Route TABLET; ORAL

Reference Listed Drug Yes

Approved since 2015-01-30

18

Boehringer Ingelheim GmbH, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is EMPAGLIFLOZIN; LINAGLIPTIN, with a corresponding application number 206073.

Regulatory Information RX

With a dosage strength 25MG;5MG

Dosage Form Route TABLET; ORAL

Reference Listed Drug Yes

Approved since 2015-01-30

Post Enquiry
POST ENQUIRY